Skip to main content
SpringerLink
Log in

Cantharidin Topical Solution 0.7%: First Approval

  • AdisInsight Report
  • Published:
Pediatric Drugs Aims and scope Submit manuscript

Abstract

Cantharidin (YCANTH™) is a proprietary drug-device combination product containing a formulation of cantharidin 0.7% topical solution (a vesicant naturally derived from blister beetles) delivered via a single-use applicator that has been developed by Verrica Pharmaceuticals Inc. for the treatment of molluscum contagiosum and is also being developed for the treatment of warts. In July 2023, YCANTH™ (cantharidin 0.7% topical solution) was approved for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older in the USA. This article summarizes the milestones in the development of cantharidin 0.7% topical solution leading to this first approval for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lacarrubba F, Micali G, Trecarichi AC, et al. New developing treatments for molluscum contagiosum. Dermatol Ther (Heidelb). 2022;12:2669–78.

    Article  PubMed  Google Scholar 

  2. Eichenfield LF, Siegfried E, Kwong P, et al. Pooled results of two randomized phase III trials evaluating VP-102, a drug-device combination product containing cantharidin 0.7% (w/v) for the treatment of molluscum contagiosum. Am J Clin Dermatol. 2021;22(2):257–65.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Guenthner S, McFalda W, Kwong P, et al. COVE-1: a phase 2, open-label study to evaluate efficacy and safety and the optimal regimen of VP-102, a proprietary drug-device product containing topical cantharidin (0.7% w/v) under occlusion for the treatment of common warts. Dermatol Ther (Heidelb). 2021;11(5):1623–34.

    Article  PubMed  Google Scholar 

  4. Vakharia PP, Chopra R, Silverberg NB, et al. Efficacy and safety of topical cantharidin treatment for molluscum contagiosum and warts: a systematic review. Am J Clin Dermatol. 2018;19(6):791–803.

    Article  PubMed  Google Scholar 

  5. Han H, Smythe C, Yousefian F, et al. Molluscum contagiosum virus evasion of immune surveillance: a review. J Drugs Dermatol. 2023;22(2):182–9.

    Article  PubMed  Google Scholar 

  6. Eichenfield LF, McFalda W, Brabec B, et al. Safety and efficacy of VP-102, a proprietary, drug-device combination product containing cantharidin, 0.7% (w/v), in children and adults with molluscum contagiosum: two phase 3 randomized clinical trials. JAMA Dermatol. 2020;156(12):1315–23.

    Article  PubMed  Google Scholar 

  7. Niazi S, Brabec B, Anschutz L, et al. A phase 2 open-label study to evaluate VP-102 for the treatment of molluscum contagiosum. J Drugs Dermatol. 2021;20(1):70–5.

    Article  PubMed  Google Scholar 

  8. Guzman A, Schairer D, Garelik J, et al. Safety and efficacy of topical cantharidin for the treatment of pediatric molluscum contagiosum: a prospective, randomized, double-blind, placebo-controlled pilot trial. Int J Dermatol. 2018;57(8):1001–6.

    Article  CAS  PubMed  Google Scholar 

  9. Del Rosso JQ, Kircik L. Topical cantharidin in the management of molluscum contagiosum: preliminary assessment of an ether-free, pharmaceutical-grade formulation. J Clin Aesthet Dermatol. 2019;12(2):27–30.

    PubMed  PubMed Central  Google Scholar 

  10. US Food & Drug Administration. Bulk drug substances nominated for use in compounding under section 503B of the Federal Food, Drug, and Cosmetic Act. 2023. https://www.fda.gov/media/94164/download. Accessed 1 Sept 2023.

  11. Cohen SR. Safety and efficacy of topical cantharidin for the treatment of molluscum contagiosum, phase 2 trial (NCT03017846). 2017. https://www.clinicaltrials.gov/. Accessed 21 Sept 2023.

  12. Verrica Pharmaceuticals Inc. YCANTH™ (cantharidin) topical solution, 0.7%: US prescribing information. 2023. https://ycanth.com/. Accessed 15 Aug 2023.

  13. Verrica Pharmaceuticals Inc. Verrica Pharmaceuticals announces FDA approval of YCANTHTM (cantharidin) topical solution as the first FDA approved treatment of pediatric and adult patients with molluscum contagiosum [media release]. 21 Jul 2023. https://www.verrica.com.

  14. US Food & Drug Administration. FDA approves first treatment for molluscum contagiosum [media release]. 24 Jul 2023. https://www.fda.gov/.

  15. Verrica Pharmaceuticals Inc. Verrica Pharmaceuticals reports second quarter 2023 financial results [media release]. 8 Aug 2023. https://verrica.com/.

  16. Torii Pharmaceutical. Torii has entered into license agreement with Verrica Pharmaceuticals to develop & commercialize VP-102 in Japan [media release]. 17 Mar 2021. https://www.torii.co.jp/.

  17. Verrica Pharmaceuticals Inc. Form 10-K. 2023. https://verrica.com/sec_filings/0000950170-23-006118/. Accessed 4 Sept 2023.

  18. Bertaux B, Prost C, Heslan M, et al. Cantharide acantholysis: endogenous protease activation leading to desmosomal plaque dissolution. Br J Dermatol. 1988;118(2):157–65.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Susan J. Keam

Authors
  1. Susan J. Keam
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susan J. Keam.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Authorship and Conflict of Interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article on the US development of the agent. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Susan J. Keam is a contracted employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.

Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability

Not applicable.

Additional information

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (PDF 206 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Keam, S.J. Cantharidin Topical Solution 0.7%: First Approval. Pediatr Drugs 26, 95–100 (2024). https://doi.org/10.1007/s40272-023-00600-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40272-023-00600-y

Search

Navigation